Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERALD basket trial of DS-8201a for HER2-amplified solid tumors identified by ctDNA
jRCT2080224635Phase 2Completed
- Sponsor
- Aichi Cancer Center
- Start
- Apr 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in Non-hematologic malignancy, sponsored by Aichi Cancer Center. Started Apr 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224635.